^
Association details:
| Biomarker: | RET L629P |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Excerpt:
A 27-year-old patient with sporadic MTC harboring multiple RET mutations (L629P, D631_R635DELINSG, and V637R)…This patient remains progression free and on therapy for more than 11 months.
DOI:
10.1158/2159-8290.CD-18-0338
